• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    There is described an immunoglobulin conjugate comprising an immunoglobulin or immunoglobulin fragment modified by one or more groups of the following formula which are covalently linked to it: <CHEM> The conjugates are useful in the treatment of cancers and are made by reaction of the immunoglobulin or immunoglobulin fragment with desacetylvinblastine acid azide.
    公开号:SU1069628A3
    申请号:SU823378149
    申请日:1982-01-11
    公开日:1984-01-23
    发明作者:Фердинанд Роулэнд Джордж；Джордж Симмондз Робин
    申请人:Лилли Индастриз Лимитед (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to methods for producing a new conjugate based on immunoglobulin, which has anti-cancer activity. A known reaction is the acylation of peptides with the aid of amino acids 111, the purpose of the invention is to obtain a new immunoglobulin conjugate that has valuable anti-cancer properties. The goal is achieved in that, according to the method, based on the reaction to produce a conjugate on a new IgG immunoglobulin or its fragment covalently associated with 1-5 groups of the formula OH-C2ll5 I 0 0CHN, the IgG immunoglobulin or its fragment is reacted with a corresponding molar an amount of desacetylbivinic acid azide at pH 8.5-9.5 and 5-25 ° C. During the reaction, a solution of azide in a suitable solvent, such as dioxane, is slowly added dropwise to an immunoglobulin buffer solution, for example, 0.35 Mr borate buffer at pH 9. Conjugate is separated by gel filtration and stored in a saturated solution of ammonium sulfate, which can be easily returned to its original state by dialysis using a borate buffer, or it can be stored in a refrigerator at or in a frozen state, for example, when -. As a result, a covalent bond is formed between one or more Vince fragments and free amino groups of an immunoglobulin molecule, for example, amino groups of lysine residues. The number of attached fragments depends on the concentration of the reactants and the duration of the reaction; however, it is usually in the order of 1.2-5. The azide reagent can be easily obtained from vinblastine, vinblastine sulphate or from deacetyl vinase by preferential hygienization of the α-ester with subsequent diazotation. Hydrazinolysis of vinblastine at moderate temperatures in a methanol solution proceeds with the formation of predominantly monohydrazide, and the reaction of such a product with hydrochloric acid and sodium nitrite in a suitable aqueous solvent gives the desired deacetylvinblastinic acid azide. Said azide can be obtained at temperatures below as indicated and without precipitating the azide, the pH is set to 9 and a solvent, such as dioxane, is mixed with water. Immunoglobulin is then added in a borate buffer having a pH of 9 and the temperature of the reaction mixture is allowed to rise to room temperature. Excess aznda is destroyed by dilute ammonia, and the conjugate is purified by gel filtration, they can be used in the treatment of animals, as well as in control and analytical experiments. As a source of immunoglobulins, the following can be used: ,} IgG goats and sheep immunized with a substance cause lung cancer; monoclonal IgG from hybridomas of mice, secreting antihuman carcinoma antibodies; are monoclonal. IgG from hybridomas of mice secreting anti-human melanoma antibodies; monoclonal IgG, hybridomas of mice, α-secretion of antibodies that react with cells of human leukemia; monoclonal IgG hybridomas of mice, secretion of antibodies that react with human neuroblastoma cells; monoclonal. IgG hybridomas of mice, secreting antibodies that react with human breast cancer antibodies: monoclonal IgG hybridomas of mice, secreting antibodies, reacting with ovarian cancers; human cell: am; monoclonal IgG hybridoma massa, secreting antibodies, reacting with osteosarcoma cancer cells of humans. As mentioned, the proposed conjugate can also be obtained by using immunoglobulin fragments, such as HB, HB or G (aB) 2 or IgM monomer derived from an antibody, for example, by proteolytic enzyme cleavage. Such substances and methods for their preparation are well known. Conjugates obtained by the proposed method can be used in the treatment of cancerous tumors. Conjugates are effective in a wide range of doses and can be used to treat adult patients at a dose of 1-10 mg / kg (vidsenin fragment), usually in the range of 3-9 mg / kg PRI me R 1. Getting sheep Vindesin-anticarcinoembryonic antigenic conjugate. Hydraid desacetylbivinic acid (6 mg) is dissolved in IN solution of HCl (340 ml) and the resulting solution is cooled to 4 ° C. 60 µl of an aqueous solution of sodium nitrite having a concentration of 10 mg / ml is added to the resulting mixture and mixed at 4c. After 5 minutes, an IN solution of NaOH (300 ml) and dioxane (120 ml) were added with vigorous stirring, after which 280 ml of a solution of a sheep anti-carcinoembryonic antigen, having a concentration of 21.3 mg / ml, were added. in the environment of borate buffer concentration of 0.34 M-at pH 8.6. The resulting mixture was stirred at room temperature for 2 hours. maintaining pH 9 using b ,, IN solution of NaOH. Excess azide is destroyed by adding IN of ammonia solution (60 ml) with stirring over an hour. The obtained product was isolated by gel filtration on a 1–25.5 cm (20 mp) column with s-gel P-6, equilibrated with phosphate buffer physiological solution. The excluded peak is collected (2.66 ml) and its protein content is determined by the method of Lowry and the content of vindesine by the method of differential spectroscopy. The conjugate thus obtained contains p1t 4.6 mol. vi.nensina per mole of IgG. Example 2. Preparation of a mildew windensin-monoclonal anti-carcinoembryonic antigen conjugate. The desiracyl hydraide hydrate (10 ME) is dissolved in hydrochloric acid (0.56 ml) and the resulting solution is cooled to 4 ° C. 100 µl of paqTBd a of sodium nitrite with a concentration of 10 mg / ml is added to the reaction of the NOI mixture and the latter is stirred at 4 ° C. After 5 minutes, with vigorous stirring, add IN a solution of sodium hydroxide (0.5 ml) and dioxane (0.2 ml), after which a solution of 0.5 m of a mono clonal anti-embryonic antigen having a concentration of 15.6 mg / ml in a solution of 0.34 borate buffer at pH 8.6. The resulting mixture was stirred at room temperature for 2 hours while maintaining pH 9 by adding O, IN caustic soda solution. Excess azide is destroyed by the addition of IN solution of ammonium hydroxide (0.1 ml) and stirring for an additional hour. The reaction product was isolated by gel filtration on a 1л27 cm (21 ml) column with P-6 bio-gel, equilibrated with phosphate-buffered saline. The eliminated peak is collected (4.07 ml) and the content of protein and vindesine in it is determined by spectroscopy at 270 and 280 nm. The conjugate thus obtained contains 2.1 mol of vindesine per mole of IgG. Example 3. Getting rabbit Vindesin-anti-mouse IgG conjugate. Deazetilvinblastic acid hydrazide (12 mg) is dissolved in IN hydrochloric acid (0.67 ml) and the resulting solution is cooled to 4 ° C. Add a 120 µm solution of sodium nitrite with a concentration of 10 mg / ml and the reaction mixture is stirred at. After 5 minutes, an IN solution of sodium hydroxide (0.6) and dioxane (0.24 ml) was added with vigorous stirring, followed by the addition of 1.0 ml of rabbit anti-mouse IgG solution with a concentration of 11.7 mg / ml in 0.34 M solution of borate buffer at pH 8.6. The resulting mixture was stirred at room temperature for 2 hours while maintaining pH 9 using O, IN sodium hydroxide solution. Excess azide is destroyed by adding IN of an ammonium hydroxide solution (0.12 ml) and stirring for an hour. The reaction product was isolated by gel filtration on a column with a size of 1.526 cm (46 ml) with P-6 bio-gel, equilibrated with phosphate-buffered saline. The eliminated peak was collected (6.22 ml) and the content of protein and vindesine was determined therein by spectroscopy at 270 and 280 nm. The conjugate thus obtained contains 3.2 moles of vindesine per mole of IgG. Example 4. The preparation of cells grown in culture medium is poured into plates with microtiter culture containing 10 cells per wall. After rooting the cells for 24 hours, the bent walls are treated with various concentrations of conjugate or control compound. After 6 days Cultivation The number of cells on the walls is estimated by direct counting using a species analyzer attached to a microscope.
    The family of adenocarcinoma cells of the human colon is treated with vindesine associated with the monoclonal anticarcinogenic antigen
    Concentration
    The number of cells in the calculation: per steak after b days. conjugated (mean + ny substance (Vindesin, µg / ml) standard deviation), 4 repetitions
    in a Culinary ratio of 2.1 moles of vindesine per mole of IgG (conjugate of Example 2), and the cytostatic effect is measured by counting the cells.
    The results of the experiments are given in the table.
    % related to control
    1b, 3 ± 4,8-10
    13.8 ± 2.5-10
    12.6 ± 1.9--10
    10, 9-10
    1.94: 0.6-10
    100
    84.6
    77.4
    66.7
    11.9
    权利要求:
    Claims (1)
    [1]
    METHOD FOR PRODUCING A CONJUGATE based on. Immunoglobulin or its fragment covalently linked to 1-5 groups of the formula, characterized in that the immunoglobulin 3gG or its fragment is reacted with an appropriate molar amount of deacetylvinblastinic acid azide at a pH of 8.5-9.5 and a temperature of 5- 25 ° C.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1069628A3|1984-01-23|Process for preparing conjugate
    US5053394A|1991-10-01|Targeted forms of methyltrithio antitumor agents
    US5030719A|1991-07-09|Cytotoxic antibody conjugates and a process for preparation thereof
    RU1787160C|1993-01-07|Method of immunoglobulin conjugated preparation
    HU189469B|1986-07-28|Process for preparing antitumour immunoglobulin-derivatives with antibody effect, comprising ricin a subordinate unit
    EP0252769A2|1988-01-13|Anti-human pulmonary carcinoma monoclonal antibody
    HU206377B|1992-10-28|Process for producing cytotoxic vinc-dimer conjugates and pharmaceutical compositions comprising same
    US4828831A|1989-05-09|New conjugates of vinblastine and its derivatives, process for preparing them and pharmaceutical compositions containing them
    JP2020531430A|2020-11-05|Anti-CTLA4 probody therapy targeting antibodies
    JP2820256B2|1998-11-05|Targeted forms of methyltrithio antitumor agents
    EP0199196A2|1986-10-29|Monoclonal antibody and method for the production thereof
    HU184736B|1984-10-29|Process for preparing anticarcinogenic immunoglobuline derivatives
    EP0171083B1|1990-11-14|Monoclonal antibody, process for preparing same, reagent for detecting cancer antigen containing the monoclonal antibody and process for preparing same
    PT93716B|1996-08-30|PROCESS FOR THE PREPARATION OF DERIVATIVES SUBSTITUTED DISSULFURET ANTITUMERS AND ANTIBACTERIALS FROM COMPOUNDS PROCESSING A METHYL-TRITIUM GROUP AND THEIR TARGET FORMS
    EP0245520B1|1992-09-16|Monoclonal antibody against glutathione s-transferase and its use in the diagnosis of cancer
    WO1988004670A1|1988-06-30|Bilirubin antigen, monoclonal antibody therefor, process for their preparation, and their use
    SU1123704A1|1984-11-15|Method of obtaining conjugated antigens
    EP0114730A2|1984-08-01|Cytocidal modified immunoglobulin and process for the preparation thereof
    KR20210018208A|2021-02-17|Conjugates of cytotoxic drugs and prodrug forms of the conjugates
    EP0332879A2|1989-09-20|Monoclonal antibody recognizing un-natural ganglioside GD3
    JP4267123B2|2009-05-27|Malathion hapten compound, antibody and assay
    JP2743015B2|1998-04-22|Monoclonal antibody specific to O-acetylated ganglioside GM &lt;3&gt;, hybridoma producing the antibody, and method for producing the same
    EP0211368A2|1987-02-25|Monoclonal anti-asialo GM1 antibody
    JP2759466B2|1998-05-28|Monoclonal antibody against swine / human egg zona pellucida common antigen and method for producing the same
    RU2181127C2|2002-04-10|Copolymers of n-vinylpyrrolidone, crotonic acid and p- crotonoylaminophenol containing covalently bound 3-hydroxyanthranilic acid | as synthetic antigens
    同族专利:
    公开号 | 公开日
    EP0056322A1|1982-07-21|
    NZ199421A|1984-08-24|
    RO82758A|1984-01-14|
    AT16603T|1985-12-15|
    AU7927482A|1982-07-22|
    PL234695A1|1982-07-19|
    ES8304149A1|1983-02-16|
    PL128529B1|1984-02-29|
    ES508633A0|1983-02-16|
    PH18031A|1985-03-06|
    RO82758B|1984-01-30|
    KR830008684A|1983-12-12|
    IE52239B1|1987-08-19|
    JPS57136529A|1982-08-23|
    HU186025B|1985-05-28|
    PT74252B|1983-08-24|
    IL64722D0|1982-03-31|
    CA1180660A|1985-01-08|
    GB2090837A|1982-07-21|
    DD201447A5|1983-07-20|
    CS235525B2|1985-05-15|
    EG15599A|1986-06-30|
    AU549495B2|1986-01-30|
    GR75182B|1984-07-13|
    IL64722A|1985-07-31|
    MX7215E|1988-01-08|
    DK5982A|1982-07-13|
    GB2090837B|1984-07-18|
    PT74252A|1982-02-01|
    ZA82122B|1983-07-27|
    EP0056322B1|1985-11-21|
    KR860001149B1|1986-08-18|
    FI820020L|1982-07-13|
    IE820023L|1982-07-12|
    BG40318A3|1986-11-14|
    DE3267474D1|1986-01-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2456224A1|1974-11-28|1976-08-12|Karl Dr Med Theurer|Cancer therapy treatment agent - consists of immune globulin with tropism for embryonic or foetic antigens|
    GB1446536A|1975-02-21|1976-08-18|Yeda Res & Dev|Pharmaceutically active compositions|
    FR2349335B1|1976-04-28|1979-10-05|Inst Int Pathologie Cellulaire|
    EP0000938B1|1977-08-22|1984-10-17|National Research Development Corporation|Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them|
    FR2437213B1|1978-09-28|1983-05-06|Cm Ind|
    JPH02328B2|1979-04-09|1990-01-08|Teijin Ltd|US4639456A|1980-06-10|1987-01-27|Omnichem S.A.|Vinblastin-23-oyl amino acid derivatives|
    CA1203164A|1982-03-09|1986-04-15|Thomas J. Mckearn|Antibody conjugates|
    DE3483336D1|1983-03-30|1990-11-08|Lilly Industries Ltd|VINCALEUKOBLASTIN DERIVATIVES.|
    GB2137210B|1983-03-30|1986-11-19|Lilly Industries Ltd|Immunoglobulin conjugates|
    GR81790B|1983-04-29|1984-12-12|Omnichem Sa|
    GB2148299B|1983-09-01|1988-01-06|Hybritech Inc|Antibody compositions of therapeutic agents having an extended serum half-life|
    US4675400A|1985-06-17|1987-06-23|Eli Lilly And Company|Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids|
    US4667030A|1985-06-17|1987-05-19|Eli Lilly And Company|Hydrazide succinimide derivatives of antineoplastic indole-dihydroindole alkaloids|
    FI860456A|1985-07-16|1987-01-17|Huhtamaeki Oy Laeaeketehdas Le|BIS-INDOLALKALOIDERS PROTEINKONJUGAT, BIS-INDOLALKALOIDER, DERAS FRAMSTAELLNING OCH ANVAENDNING.|
    EP0232693A3|1985-12-16|1988-04-06|La Region Wallonne|Conjugates of vinblastine and its derivatives, process for their preparation and pharmaceutical compositions containing them|
    IL82579D0|1986-05-27|1987-11-30|Lilly Co Eli|Immunoglobulin conjugates|
    US4801688A|1986-05-27|1989-01-31|Eli Lilly And Company|Hydrazone immunoglobulin conjugates|
    FR2626882B1|1988-02-08|1991-11-08|Ire Celltarg Sa|VINCA DERIVATIVE CONJUGATES COMPRISING A DETERGENT CHAIN IN POSITION C-3|
    US5144012A|1988-08-08|1992-09-01|Eli Lilly And Company|Cytotoxic drug conjugates|
    US5094849A|1988-08-08|1992-03-10|Eli Lilly And Company|Cytotoxic antibody conjugates of hydrazide derivatized vinca analogs via simple organic linkers|
    US5028697A|1988-08-08|1991-07-02|Eli Lilly And Company|Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers|
    US5006652A|1988-08-08|1991-04-09|Eli Lilly And Company|Intermediates for antibody-vinca drug conjugates|
    US5043340A|1990-04-03|1991-08-27|Eli Lilly And Company|Derivatives of 4-desacetyl VLB C-3 carboxhydrazide|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB8100847|1981-01-12|
    [返回顶部]